Purchase this article with an account.
Teresa Rolle, Laura Dallorto, Gemma Caterina Rossi, Fiamma Campana; BRINZOLAMIDE-TIMOLOL FIXED COMBINATION AND TRAVOPROST AS MTMT IN PRIMARY OPEN ANGLE GLAUCOMA: LONG TERM EFFICACY AND TOLERABILITY. Invest. Ophthalmol. Vis. Sci. 2016;57(12):6420. doi: https://doi.org/.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate long-term efficacy of brinzolamide-timolol fixed combination and travoprost in terms of IOP values, tolerability and visual impairment in POAG eyes.
This was a multicenter, observational cohort, 12 month study. Glaucomatous patients with different antiglaucomatous therapies were switched to brinzolamide-timolol fixed combination twice a day and travoprost 0.004 % once a day as maximum tolerate medical therapy (MTMT). Complete ophthalmic examination comprehensive of IOP, BCVA, SAP 24-2 SITA STANDARD, ocular surface status (tear film break-up time and corneal staining) and quality of life (OSDI) perception was performed at baseline (T0), after 6 months (T1) and after 12 months (T2). Statistical analysis was performed with Friedman test, statistical significance was considered for p<0.05.
38 POAG patients (mean age 70.04±9.37ys, 12F/26M) were enrolled in the study and treated with B+T FC TID and travoprost 0.004% once a day. 42.65% of the 68 eyes included in the study were in therapy with two drugs and 57.35% received three anti-glaucomatous drugs (88% were BAK-preserved drugs). The previous therapy was changed for lack of efficacy and/or intolerance. B+T FC TID and travoprost 0.004% were effective in reducing intraocular pressure: the T1 mean IOP was 16% lower than the T0 mean IOP (15.68 and 18.76 mmHg respectively, p <0.001). After 12 months mean IOP value was 15.95 ± 2.76 mmHg (p<0.001). In table 1 BCVA, MD and PSD, BUT and corneal staining mean values are illustrated. Ocular Surface Disease Index mean value was lower after 6 months and had a further decrease after 12 months (33.62 ± 10.74, 30.32 ±10.45, 28.48 ± 9.85 at T0,T1 and T2 respectively, p<0.001). Only two patients discontinued the therapy (one for intolerance, the other for failure to reach target IOP)
After the switch from a previous therapy to a brinzolamide-timolol fixed combination and travoprost a significant reduction in IOP was obtained with preservation of functional parameters (BCVA, MD and PSD SAP values). Furthermore both quality of life and ocular surface status statistically improved. Brinzolamide-timolol fixed combination associated with travoprost is therefore effective and safe for the ocular surface status.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.
This PDF is available to Subscribers Only